Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Active-controlled, Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13vpnc Compared With A 7vpnc In Healthy Infants In China

NCT01692886 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01692886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01692886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Active-controlled, Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13vpnc Compared With A 7vpnc In Healthy Infants In China
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2012
Completion date
April 30, 2014
Enrollment
1,674 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infection